Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
"This is an important strategic milestone in the development of
Reviroc(TM) and we are very pleased with the orphan drug designations
received from the FDA," says Dr.
The FDA's orphan drug designation is reserved for new therapies being
developed to treat diseases or conditions that affect fewer than 200,000
Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft.
About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development
company with cell based products in clinical development. The company
develops products that offer novel treatment options for terminally ill
cancer patients and address significant unmet medical needs. The key focus
indication for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures performed in blood cancer patients. Kiadis Pharma
is headquartered in
SOURCE Kiadis Pharma